No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BVS Bioventus
- 7.275
- +0.105+1.46%
Trading Jul 22 14:55 ET
464.35MMarket Cap-22734P/E (TTM)
7.300High7.060Low186.05KVolume7.180Open7.170Pre Close1.34MTurnover0.79%Turnover RatioLossP/E (Static)63.83MShares7.38552wk High2.71P/B172.29MFloat Cap2.82152wk Low--Dividend TTM23.68MShs Float19.941Historical High--Div YieldTTM3.35%Amplitude0.800Historical Low7.199Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Bioventus(BVS.US) Officer Sells US$14,253.63 in Common Stock
$Bioventus(BVS.US)$ Officer CHURCH KATRINA J sold 2,559 shares of common stock on Jun 21, 2024 at an average price of $5.57 for a total value of $14,253.63.Source: Announcement What is statement of ch
Bioventus(BVS.US) Officer Sells US$32,885.28 in Common Stock
$Bioventus(BVS.US)$ Officer D'Adamio Anthony sold 5,904 shares of common stock on Jun 21, 2024 at an average price of $5.57 for a total value of $32,885.28.Source: Announcement What is statement of ch
Bioventus(BVS.US) Officer Sells US$51,349.83 in Common Stock
$Bioventus(BVS.US)$ Officer Singleton Mark Leonard sold 9,219 shares of common stock on Jun 21, 2024 at an average price of $5.57 for a total value of $51,349.83.Source: Announcement What is statement
Here's Why You Should Consider Buying Bioventus (BVS) Stock
J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
Comments
The company’s quarterly sales reached $129.457 million, exceeding the analyst consensus estimate of $118.380 million by 9.36 percent.
Bioventus Inc. (Nasdaq: BVS), a company in the field of active healing solutions, has recently announced its financial outcomes for the quarter ending March 30, 2024, displaying remarkable performance and growth that has surpassed expectations on multiple fronts. The company's earnings pe...
Bioventus Inc. (Nasdaq: BVS), a company in the field of active healing solutions, has recently announced its financial outcomes for the quarter ending March 30, 2024, displaying remarkable performance and growth that has surpassed expectations on multiple fronts. The company's earnings pe...
$Bioventus(BVS.US$ Target 6
1
follow for nightly watchlist 👊
$Amgen(AMGN.US$ $Blue Apron(APRN.US$ $Broadcom(AVGO.US$ $Booking Holdings(BKNG.US$ $Bioventus(BVS.US$ $Caterpillar(CAT.US$ $Cohen(COHN.US$ $Freedom Holding(FRHC.US$ $F45 Training(FXLV.US$ $Globant(GLOB.US$ $AMTD Digital(HKD.US$ $Intuit(INTU.US$ $ServiceNow(NOW.US$ $Napco Security Technologies(NSSC.US$ $Sunrun(RUN.US$ $Schlumberger(SLB.US$
$Amgen(AMGN.US$ $Blue Apron(APRN.US$ $Broadcom(AVGO.US$ $Booking Holdings(BKNG.US$ $Bioventus(BVS.US$ $Caterpillar(CAT.US$ $Cohen(COHN.US$ $Freedom Holding(FRHC.US$ $F45 Training(FXLV.US$ $Globant(GLOB.US$ $AMTD Digital(HKD.US$ $Intuit(INTU.US$ $ServiceNow(NOW.US$ $Napco Security Technologies(NSSC.US$ $Sunrun(RUN.US$ $Schlumberger(SLB.US$
1
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg